Pyxis Oncology, Inc. (PYXS)
Nasdaq · Healthcare · Biotechnology
$2.24+4.67%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $268M
- 52-week range
- $1.03 – $5.55
- 52-week change
- −16.08%
- EPS (trailing)
- −$1.40
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $13.9M (−14.17%)
- Net income
- −$79.6M
- Operating margin
- −609.2%
- Diluted EPS
- −$1.28
- Free cash flow
- −$63.5M
From the company’s annual report on SEC EDGAR.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc.
Headquarters: Boston, United States · 56 employees · pyxisoncology.com